Details of Disease

General Information of Disease (ID: DIS24TP9)

• Disease Name: Chemotherapy-induced nausea
• Disease Class: MD90: Nausea/vomiting
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DIS24TP9: Chemotherapy-induced nausea
• ICD Code:
  ICD-11: ICD-11: MD90
  ICD-10: ICD-10: R11
  ICD-9: ICD-9: 787
  Expand ICD-9: 787

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Marinol	DM70IK5	Approved	Small molecular drug	[1]
Ondansetron	DMOTQ1I	Approved	Small molecular drug	[2]
Rolapitant	DM8XP26	Approved	Small molecular drug	[3]
Selegiline	DM6034S	Approved	Small molecular drug	[4]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Angiotensin-(1-7)	DM76GZ0	Phase 3	Small molecular drug	[5]
Netupitant	DMEKAYI	Phase 3	Small molecular drug	[6]
KB-6806	DMZ4MCG	Phase 2	Small molecular drug	[7]
AD-337	DM8VQ1S	Phase 1	NA	[7]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Casopitant	DMBQYO0	Withdrawn from market	Small molecular drug	[8]
GSK 679769	DMSV6KP	Discontinued in Phase 2	NA	[7]
SLV-323	DMHRYX6	Discontinued in Phase 1	NA	[7]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Clinical pipeline report, company report or official report of INSYS Therapeutics.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2290).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5749).
• [4] Clinical pipeline report, company report or official report of GlaxoSmithKline.
• [5] ClinicalTrials.gov (NCT01121120) Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients. U.S. National Institutes of Health.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5742).
• [7] Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5758).
• [9] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [10] A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014 Jul;25(7):1333-9.